Effects of thiazolidinedione therapy on inflammatory markers of type 2 diabetes: A meta-analysis of randomized controlled trials

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Chen, Rui ^a   Yan, Jinchuan ^a   Liu, Peijing ^a   Wang, Zhongqun ^a  

^a JIANGSU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; GELATINASE B; HIGH SENSITIVITY C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; AUTACOID;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DISEASE MARKER; HUMAN; INFLAMMATION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; BLOOD; DIABETES MELLITUS, TYPE 2; IMMUNOLOGY;

BIOMARKERS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84928729314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123703     Document Type: Article

References (51)

1. Virdis A, Dell'Agnello U, Taddei S. Impact of inflammation on vascular disease in hypertension. Maturitas. 2014; 78:179-183. doi: 10.1016/j.maturitas PMID: 24846805
2. Klingenberg R, Luscher TF. Inflammation in coronary artery disease and acute myocardial infarction - is the stage set for novel therapies? Curr Pharm Des. 2012; 18: 4358-69. doi: 10.1016/j.maturitas.2014.04.012 PMID: 24846805
3. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009; 94:3171-82. doi: 10.1210/jc.2008-2534 PMID: 19509100
4. Cruz NG, Sousa LP, Sousa MO, Pietrani NT, Fernandes AP, Gomes KB. The linkage between inflammation and Type 2 diabetes mellitus. Diabetes Res Clin Pract.2013; 99:85-92. doi: 10.1016/j.diabres.2012.09.003 PMID: 23245808
5. Paneni F, Costantino S, Cosentino F. Insulin resistance, diabetes, and cardiovascular risk.Curr Atheroscler Rep. 2014; 16: 419. doi: 10.1007/s11883-014-0419-z PMID: 24781596
6. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.CMAJ. 2012; 184: E675-83. doi: 10.1503/cmaj.112102 PMID: 22761478
7. Subramani PA, Reddy MC, Narala VR. The need for physiologically relevant peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligands. Endocr Metab Immune Disord Drug Targets. 2013; 13:175-83. PMID: 23713695
8. Ren L, Liu N, Zhi H, Li Y, Li Y, Tang R, et al. Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro. Cardiovasc Diabetol. 2011; 10:10. doi: 10.1186/1475-2840-10-10 PMID: 21269478
9. Imig JD, Walsh KA, Hye Khan MA, Nagasawa T, Cherian-Shaw M, Shaw SM, et al. Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats.Exp Biol Med (Maywood). 2012; 237:1402-12. doi: 10.1258/ebm.2012.012225 PMID: 23354399
10. Celinski K, Dworzanski T, Fornal R, Korolczuk A, Madro A, Slomka M. Comparison of the anti-inflammatory and therapeutic actions of PPAR-gamma agonists rosiglitazone and troglitazone in experimental colitis.J Physiol Pharmacol. 2012; 63:631-40. PMID: 88479
11. Ramkalawan H, Wang YZ, Hurbungs A, Yang YF, Tian FF, Zhou WB, et al. Pioglitazone, PPARγ agonist, attenuates experimental autoimmune neuritis. Inflammation. 2012; 35:1338-47. doi: 10.1007/s10753-012-9447-4 PMID: 22389055
12. Meisner F, Walcher D, Gizard F, Kapfer X, Huber R, Noak A, et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial.Arterioscler Thromb Vasc Biol. 2006; 26:845-50. PMID: 16410460
13. Halvorsen B, Heggen E, Ueland T, Smith C, Sandberg WJ, Damas JK, et al. Treatment with the PPAR gamma agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome.Eur J Endocrinol.2010; 162: 267-73. doi: 10.1530/EJE-09-0706 PMID: 19926782
14. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol.2005; 5:13. PMID: 15840177
15. Bertrand OF, Poirier P, Rodés-Cabau J, Rinfret S, Title LM, Dzavik V, et al. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial. Atherosclerosis. 2010; 211: 565-73. doi: 10.1016/j.atherosclerosis.2010.06.005 PMID: 20594555
16. Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance ordiabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging. 2011; 4:1110-8. doi: 10.1016/j.jcmg.2011.08.00 PMID: 21999871
17. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005; 45: 1925-31. PMID: 15963388
18. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J. 2007; 153:445.e1-6. PMID: 17307426
19. Agarwal R. Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am J Physiol Renal Physiol. 2006; 290: F600-5. PMID: 16159895
20. Chan DT, Watts GF, Irish AB, Dogra GK. Rosiglitazone does not improve vascular function in subjects with chronic kidney disease. Nephrol Dial Transplant. 2011; 26: 3543-9. doi: 10.1093/ndt/gfr049 PMID: 21378155
21. Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy andtolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic Americanpatients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Clin Ther. 2007; 29: 1900-14. PMID: 1803519
22. Rosenfeld ME. Inflammation and atherosclerosis: direct versus indirect mechanisms.Curr Opin Pharmacol. 2013; 13:154-60. doi: 10.1016/j.coph.2013.01.003 PMID: 23357128
23. van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus.Mediators Inflamm.2010; 792393. doi: 10.1155/2010/792393 PMID: 20634940
24. Finn AV, Oh JS, Hendricks M, Daher M, Cagliero E, Byrne RM, et al. Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitusrandomized to rosiglitazone or placebo. Mediators Inflamm. 2009; 157:383.e1-8. doi: 10.1016/j.ahj.2008.11.013 PMID: 19185649
25. Schöndorf T, Musholt PB, Hohberg C, Forst T, Lehmann U, Fuchs W, et al. The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronicinflammation in type 2 diabetes patients: results from the PIOfix study. J Diabetes Sci Technol. 2011; 5: 426-32. PMID: 21527115
26. Hartemann-Heurtier A, Halbron M, Golmard JL, Jacqueminet S, Bastard JP, Rouault C, et al. Effects of bed-time insulin versus pioglitazone on abdominal fat accumulation, inflammation and gene expressionin adipose tissue in patients with type 2 diabetes. Diabetes Res Clin Pract 86:37-43. doi: 10.1016/j.Diabres.2009.06.028 PMID: 19683825
27. Kiyici S, Ersoy C, Kaderli A, Fazlioglu M, Budak F, Duran C, et al. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1levels in drug naive type 2 diabetic patients. Diabetes Res Clin Pract. 2009; 86: 44-50. doi: 10.1016/j.diabres.2009.07.004 PMID: 19674806
28. Forst T, Karagiannis E, Lübben G, Hohberg C, Schöndorf T, Dikta G, et al. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis 197: 311-7. PMID: 17588584
29. Fidan E, Onder Ersoz H, Yilmaz M, Yilmaz H, Kocak M, Karahan C, et al. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol. 2011; 48: 297-302. doi: 10.1007/s00592-011-0276-y PMID: 21424914
30. Marfella R, D'Amico M, Esposito K, Baldi A, Di Filippo C, Siniscalchi M, et al. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects ofrosiglitazone treatment. Diabetes. 2006; 55: 622-32. PMID: 16505224
31. Hong SJ, Kim ST, Kim TJ, Kim EO, Ahn CM, Park JH, et al. Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation. Arterioscler Thromb Vasc Biol. 2010; 30:2655-65. doi: 10.1161/ATVBAHA.110.212670 PMID: 21030718
32. Ogasawara D, Shite J, Shinke T, Watanabe S, Otake H, Tanino Y, et al. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J 73: 343-51. PMID: 19096190
33. Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2diabetes mellitus and coronary artery disease. Metabolism. 2007; 56: 1396-401. PMID: 17884451
34. Hanefeld M, Pfützner A, Forst T, Kleine I, Fuchs W. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect ofpioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetesreceiving stable basal insulin therapy: the PIOCOMB study. Cardiovasc Diabetol. 2011; 10:65. doi: 10.1186/1475-2840-10-65 PMID: 21756323
35. Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, et al. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen innormotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone. Med Princ Pract. 2009; 18: 266-71. doi: 10.1159/ 000215722 PMID: 19494532
36. Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, Bank AJ. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med. 2007; 12: 311-8. PMID: 18048467
37. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008; 299: 1561-73. doi: 10.1001/jama.299.13.1561 PMID: 18378631
38. Langenfeld MR, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2diabetes mellitus: results from a controlled randomized study. Circulation. 2005; 111: 2525-31. PMID: 15883215
39. Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, et al. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia.2013; 56:2153-63. doi: 10.1007/s00125-013-2976-z PMID: 23811853
40. Pop-Busui R, Oral E, Raffel D, Byun J, Bajirovic V, Vivekanandan-Giri A, et al. Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus. Metabolism. 2009; 58:989-94. doi: 10.1016/j.metabol.2009.02.020 PMID: 19394661
41. Derosa G, Mereu R, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, et al. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. J Clin Pharm Ther. 2010; 35:565-79. doi: 10.1111/j.1365-2710.2009.01132.X PMID: 20831680
42. Martens FM, Rabelink TJ, op 't Roodt J, de Koning EJ, Visseren FL. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J.2006; 27:1605-9. PMID: 16762982
43. Kharazmkia A, Ahmadpoor P, Ziaei S, Salamzadeh J, Pour-Reza-Gholi F, Khoshdel A, et al. Effects of pioglitazone on blood glucose and inflammatory markers of diabetic kidney transplant patients: a randomized controlled trial.Iran J Kidney Dis. 2014; 8: 408-16 PMID: 25194409
44. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002; 106: 679-84. PMID: 12163427
45. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond). 2005; 109:143-59. PMID: 16033329
46. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002; 53:31-47. PMID: 11744011
47. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsoufis C, Marinou K, et al. Differences in inflammatory and thrombotic markers between unstable angina and acute myocardial infarction.Int J Cardiol. 2007; 115:203-7. PMID: 16787670
48. Gada E, Owens AW, Gore MO, See R, Abdullah SM, Ayers CR, et al. Discordant effects of rosiglitazone on novel inflammatory biomarkers.Am Heart J. 2013; 165:609-14. doi: 10.1016/j.ahj.2013.01.006 PMID: 23537979
49. Andreozzi F, Laratta E, Cardellini M, Marini MA, Lauro R, Hribal ML, et al. Plasma interleukin-6 levels are independently associated with insulin secretion in a cohort of Italian-Caucasian nondiabetic subjects. Diabetes. 2006; 55:2021-4. PMID: 16804071
50. Monroy A, Kamath S, Chavez AO, Centonze VE, Veerasamy M, Barrentine A, et al. Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic systemin skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans.Diabetologia. 2009; 52:2169-81. doi: 10.1007/s00125-009-1451-3 PMID: 19633828
51. Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Shurygina E, Barbarash O. Insulin resistance and inflammation markers in myocardial infarction.J Inflamm Res. 2013; 6:83-90. doi: 10.2147/JIR.S43081 PMID: 23837002